BRIEF-AstraZeneca announces results from SYMBICORT study

* SYMBICORT demonstrated comparable risk of serious asthma-related events and lower risk of asthma exacerbations compared to Budesonide alone
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.